The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine

被引：7

作者：

Eron, Joseph J., Jr. ^{[1
]}

Bosch, Ronald J.

Bettendorf, Daniel

Petch, Leslie

Fiscus, Susan

Frank, Ian

机构：

[1] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA

[2] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA

[3] Univ N Carolina, Sch Med, Dept Microbiol, Chapel Hill, NC 27515 USA

[4] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2007年 / 45卷 / 02期

关键词：

D O I：

10.1097/QAI.0b013e318050d61f

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：249 / 251

页数：3

共 10 条

[1] Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection [J].

Flandre, Philippe ;

Chappey, Colombe ;

Marcelin, Anne Genevieve ;

Ryan, Kirk ;

Maa, Jen-Fue ;

Bates, Mike ;

Seekins, Daniel ;

Bernard, Marie Charlotte ;

Calvez, Vincent ;

Molina, Jean Michel .

JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (03) :392-398

[2] Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: A randomized, placebo-controlled trial, ACTG 307 [J].

Frank, I ;

Bosch, RJ ;

Fiscus, S ;

Valentine, F ;

Flexner, C ;

Segal, Y ;

Ruan, P ;

Gulick, R ;

Wood, K ;

Estep, S ;

Fox, L ;

Nevin, T ;

Stevens, M ;

Eron, JJ .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (09) :916-926

[3] NOVEL MUTATION IN THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE GENE THAT ENCODES CROSS-RESISTANCE TO 2',3'-DIDEOXYINOSINE AND 2',3'-DIDEOXYCYTIDINE [J].

GU, ZX ;

QING, G ;

LI, XG ;

PARNIAK, MA ;

WAINBERG, MA .

JOURNAL OF VIROLOGY, 1992, 66 (12) :7128-7135

[4] Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel [J].

Hirsch, MS ;

Brun-Vézinet, F ;

Clotet, B ;

Conway, B ;

Kuritzkes, DR ;

D'Aquila, RT ;

Demeter, LM ;

Hammer, SM ;

Johnson, VA ;

Loveday, C ;

Mellors, JW ;

Jacobsen, DM ;

Richman, DD .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (01) :113-128

[5]

Hughes MD, 2000, STAT MED, V19, P3171, DOI 10.1002/1097-0258(20001215)19:23&lt

[6]

3171::AID-SIM619&gt

[7]

3.0.CO

[8]

2-T

[9] Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: A randomized placebo-controlled trial [J].

Molina, JM ;

Marcelin, AG ;

Pavie, J ;

Heripret, L ;

De Boever, CM ;

Troccaz, M ;

Leleu, G ;

Calvez, V .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (06) :840-847

[10] Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients [J].

Winters, MA ;

Bosch, RJ ;

Albrecht, MA ;

Katzenstein, DA .

JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (04) :537-540

← 1 →